SITC 2022 | Vidutolimod, a novel TLR9 agonist, in high-risk resectable melanoma

Diwakar Davar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, describes the mechanism of action of vidutolimod. The novel CpG-A Toll-like receptor 9 (TLR9) inhibitor primarily targets the innate immune system and a Phase II pilot study (NCT04401995) is currently assessing the investigational drug with nivolumab in patients with melanoma. Dr Davar additionally highlights the benefits of assessing vidutolimod in the neoadjuvant setting, where the immune cells that the drug targets in the lymph nodes can be easily elucidated. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.